Patent Application
20080058366
The following are representative regimens in accord with the present invention:
Daytime Dosage
120 mg pseudoephedrine HCl and 2.5 mg methscopolamine nitrate (12 hour dosage)
Nighttime Dosage
8 mg chlorpheniramine maleate
This regimen would have the anticholinergic agent methscopolamine in the daytime formulation, but not at night. Notably, chlorpheramine is a first-generation sedating antihistamine and, as noted, has anticholinergic drying properties itself. Dosing of such an agent is preferably avoided during the daytime unless sedation is desired at that time. Methscopolamine is considered a non-sedating agent, not crossing the blood-brain barrier easily. While a non-sedating agent is preferred, other agents having anticholinergic properties might likewise be incorporated.
Daytime Dosage
120 mg pseudoephedrine HCl and 2.5 mg methscopolamine nitrate (12 hour dosage)
Nighttime Dosage
180 mg fexofenadine (24 hour dosage)
This regimen would have the nonsedating anticholinergic agent methscopolamine in the daytime formulation and not at night. Fexofenadine utilized in this example is a second-generation non-sedating antihistamine and, as noted, does not have anticholinergic drying properties. Other non-sedating antihistamines might be similarly utilized. This regimen would be appropriate for an individual whose symptoms of rhinorrhea or post-nasal drip are bothersome during the day and relatively inconsequential at night allowing a reprieve from anticholinergic medication at night.
Daytime Dosage
120 mg pseudoephedrine HCl and 2.5 mg methscopolamine nitrate
Nighttime Dosage
180 mg fexofenadine and 1.25 mg methscopolamine
This regimen would have the nonsedating anticholinergic agent methscopolamine in the daytime formulation and an attenuated dosage of methscopolamine at night. This regimen would be appropriate for an individual whose symptoms of rhinorrhea or post-nasal drip are bothersome during the day and somewhat at night, necessitating a drying agent. It might also be useful for an individual who is symptomatic both day and night, but also experiences side effects of anticholinergic agents necessitating a lower dosage.
Daytime Dosage
120 mg pseudoephedrine HCl, 60 mg fexofenadine and 2.5 mg methscopolamine nitrate (12 hour dosage)
Nighttime Dosage
60 mg fexofenadine (12 hour dosage)
This regimen is similar to Example 2, however, the antihistamine fexofenadine is divided in the daytime and nighttime dosage.
Daytime Dosage
120 mg pseudoephedrine HCl and 2.5 mg methscopolamine nitrate (12 hour dosage)
Nighttime Dosage
60 mg pseudoephedrine HCl and 1.25 mg methscopolamine nitrate (12 hour dosage)
This regimen has no antihistamine and is intended for treatment of nasal congestion and rhinorrhea. It might be suitable for individuals with rhinorrhea due to viral respiratory tract infections (“colds”) as the histamine mechanism is not a usual mechanism for cold symptoms. Notably, as decongestant can produce insomnia in some individuals, both decongestant pseudoephedrine and methscopolamine dosage are illustrated to be attenuated at night in this example.
The present invention is a treatment regimen, a pharmaceutical package containing a treatment regimen, and a method for treating rhinitis with rhinorrhea. The treatment regimen includes a daytime dosage unit containing medication for treating rhinitis and an anticholinergic agent for treating rhinorrhea to maximize the therapeutic advantages of the anticholinergic agent, and a nighttime dosage unit containing medication for treating rhinitis and an attenuated dosage of anticholinergic agent or no anticholinergic agent in order to minimize the side effects of the anticholinergic agent. The pharmaceutical package is a prefilled, unifying dispensing container containing at least two different dosage units of medications for treating rhinitis with rhinorrhea where one dosage unit is for daytime dosing and the other dosage unit is for nighttime dosing, indicia for distinguishing the daytime dosage unit and the nighttime dosage unit and signifying their use together, and instructions for coordinating the daytime dosage unit and the nighttime dosage unit as a treatment regimen for treating rhinitis with rhinorrhea. Such containers as boxes, packets or blister packs are well known in the art. The dosage units may be in the form of tablet, pill, capsule, caplet, powders, liquids, gels, some of which may require reconstituting, or any generally recognized oral form of medication.
Although the preferred embodiments of the present invention have been described herein, the above description is merely illustrative. Further modification of the invention herein disclosed will occur to those skilled in the respective arts and all such modifications are deemed to be within the scope of the invention as defined by the appended claims.
This application claims the benefit of U.S. Provisional Patent Application No. 60/824,714, filed Sep. 6, 2006.
| Number | Date | Country | |
|---|---|---|---|
| 60824714 | Sep 2006 | US |
